Certara (CERT) risk factors, FY2024 10-K

Risks Related to Our Industry

1. 01Deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development by regulatory authorities or academic institutions could damage our reputation or reduce the demand for our products and services
2. 02We compete in a competitive and highly fragmented market
3. 03Changes or delays in government regulation, executive action or administrative decision-making relating to the biopharmaceutical industry could decrease the need for some of the services we provide
4. 04Reduction in R&D spending by our customers for a variety of reasons, as well as delays in the drug discovery and development process, may reduce demand for our products and services and negatively impact our results of operations and financial condition
5. 05Consolidation within the biopharmaceutical industry may reduce the pool of potential customers for our products and services or reduce the number of licenses for our software products
6. 06Evolving corporate governance and public disclosure regulations and expectations, including with respect to sustainability matters, could expose us to risks

Risks Related to Our Business

1. 07Our continued revenue growth depends on our ability to successfully increase our customer base, expand our relationships and the products and services we provide to our existing customers, and enter new markets and expand geographies
2. 08We depend on highly qualified personnel and may not be able to retain these employees or recruit additional qualified personnel, which could harm our business
3. 09If our independent contractors are characterized as employees, we could be subject to material adverse effects on our business and employment and withholding liabilities
4. 10Delays or defects in the release of new or enhanced software or other biosimulation tools may result in increased cost to us, delayed market acceptance of our products, diminished demand for our products, delayed or lost revenue, and liability
5. 11If our existing customers do not renew their software licenses, do not buy additional solutions from us or renew at lower prices, our business and operating results will suffer
6. 12existing customers. Any dissatisfaction from existing customers may adversely impact our ability to sell our solutions to new customers
7. 13We have government customers and have received government grants, which subject us to risks including early termination, audits, investigations, sanctions, or penalties
8. 14revenue sources, we may operate with less certainty and shorter known time horizons on public sector commitments and contracts
9. 15Our historic growth rates may not be sustainable or indicative of future growth
10. 16Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our business, financial condition and results of operations may suffer
11. 17Our estimated addressable market is subject to inherent challenges and uncertainties. If we have overestimated the size of our addressable market or the various markets in which we operate, our future growth opportunities may be limited
12. 18time as our strategy evolves. While we believe the information on which we base our TAM is generally informative, such expectations, assumptions and estimates are inherently imprecise
13. 19Adverse global economic conditions could have a negative effect on our business, results of operations and financial condition and liquidity
14. 20We are subject to economic, political and other risks associated with the operation of a global business that could negatively affect our business, results of operations and financial condition
15. 21Our failure to comply with trade compliance and economic sanctions laws and regulations of the United States and other applicable international jurisdictions could materially adversely affect our reputation and results of operations
16. 22Current and future litigation against us, which may arise in the ordinary course of our business, could be costly and time consuming to defend
17. 23Our insurance coverage may not be sufficient to avoid material impact on our financial position resulting from claims or liabilities against us, and we may not be able to obtain insurance coverage on attractive terms, or at all, in the future
18. 24If we fail to perform our services in accordance with contractual requirements, regulatory standards and ethical considerations, we could be liable for significant costs or penalties and our reputation could be harmed
19. 25We derive a significant percentage of our revenues from a key group of customers, and the loss of one or more of our major customers could materially and adversely affect our business, results of operations and/or financial condition
20. 26We expect to devote substantial financial resources to our ongoing and planned activities, including the continued investment in our biosimulation software platform and strategic partnerships and acquisitions
21. 27Our bookings might not accurately predict our future revenue, and we might not realize all or any part of the anticipated revenue reflected in our bookings
22. 28Our business may be subject to risks arising from catastrophic events, including natural disasters, significant or extreme weather events, outbreaks of war or terrorism, epidemic diseases, pandemics, and public health crises

Risks Related to Intellectual Property, Information Technology and Data Privacy

1. 29We rely on third-party providers of cloud-based infrastructure to host our software solutions. Any disruption in the operations of these third-party providers, limitations on capacity or interference with our use could adversely affect our business, financial condition, reputation and results of operations
2. 30management requirements increases, our business, financial condition and results of operations could be harmed
3. 31Some of our software solutions utilize third-party open source software, and any failure to comply with the terms of one or more of these open source licenses could adversely affect our business, subject us to litigation and create potential liability
4. 32If our cybersecurity measures are breached or unauthorized or unlawful access to customer or other proprietary data occurs, our solutions may be perceived as not being secure, customers may reduce the use of or stop using our solutions and/or we may incur significant liabilities
5. 33We are subject to numerous privacy and cybersecurity laws and related contractual requirements, and our failure to comply with those obligations could cause us significant harm, including financial losses and reputational harm
6. 34Data privacy and security laws and regulations often govern the handling of information about individuals, including personal health information and require the use of standard contracts, privacy and security standards and other administrative simplification provisions
7. 35The GDPR and the UK GDPR regulate our processing of personal data, and imposes stringent requirements. Failure to comply with the GDPR or UK GDPR may result in fines up to the greater of €20 million or 4.0% of worldwide gross annual revenue and applies to services providers such as us under each of GDPR and UK GDPR
8. 36We may be unable to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights
9. 37Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
10. 38If we fail to comply with certain healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected

Risks Related to Our Indebtedness

1. 39Our indebtedness could materially adversely affect our financial condition and our ability to operate our business, react to changes in the economy or industry or pay our debts and meet our obligations under our debt and could divert our cash flow from operations to debt payments
2. 40our capital requirements. In addition, the terms of our existing or future debt agreements may restrict us from pursuing any of these alternatives
3. 41Restrictive covenants governing our Credit Agreement may restrict our ability to pursue our business strategies, and failure to comply with any of these restrictions could result in acceleration of our debt

Risks Related to our Financial Statements and Results

1. 42Impairment of goodwill or other intangible assets may adversely impact future results of operations
2. 43Our ability to use our net operating losses (“NOLs”) and R&D tax credit carryforwards to offset future taxable income may be subject to certain limitations

Risks Related to Ownership of Our Common Stock

1. 44Future sales, or the perception of future sales, of our common stock by us or our existing stockholders in the public market could cause the market price for our common stock to decline
2. 45Arsenal holds a substantial amount of our outstanding common stock, and its interests may be different than the interests of other holders of our common stock